Drug intelligence / Profile preview

CUSA-081

Development stage: Phase 3
Lead developer: Chiesi
Modality: Metabolic Enzymes → Therapeutic Enzymes → Recombinant Proteins and Enzymes, Small Molecules
Administration: Intraluminal

Overview

CUSA-081 is a novel formulation of reteplase, a recombinant tissue plasminogen activator (tPA) developed for the restoration of central venous access device (CVAD) functionality in patients with catheter dysfunction due to thrombosis. Reteplase acts as a plasminogen activator, promoting the conversion of plasminogen to plasmin and thereby facilitating fibrin clot dissolution. The drug is administered intraluminally into dysfunctional CVADs to clear thrombotic occlusions and restore device patency. CUSA-081 has been evaluated in phase 3 clinical trials comparing its efficacy and safety against alteplase and placebo for this indication[2][4][7][9].

Brand names: RETAVASE
Other names: CUSA-081CUSA081CUSA 081diluted reteplase

Targets

PLG (Plasminogen)

Beyond the preview

Go deeper on CUSA-081.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CUSA-081.

Explore the full profile